October 7, 2024 02:44 PM EDTUpdated October 8, 07:45 AM
Pharma
Law

Supreme Court de­clines to re­view patent bat­tle over in­hala­tion pow­der Yutrepia

Katherine Lewin

News Reporter

Liq­uidia’s stock $LQ­DA rose about 10% on Mon­day fol­low­ing a win in the US Supreme Court for its tre­pros­tinil in­hala­tion pow­der Yutrepia.

Liq­uidia has been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times